Andy Pasternak News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Andy pasternak. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Andy Pasternak Today - Breaking & Trending Today
StockNews.com began coverage on shares of Horizon Therapeutics Public (NASDAQ:HZNP – Get Rating) in a research note published on Tuesday morning. The brokerage issued a buy rating on the biopharmaceutical company’s stock. Other equities analysts have also issued research reports about the company. Wells Fargo & Company lowered Horizon Therapeutics Public from an overweight rating […] ....
StockNews.com assumed coverage on shares of Horizon Therapeutics Public (NASDAQ:HZNP – Get Rating) in a report published on Tuesday. The firm issued a buy rating on the biopharmaceutical company’s stock. HZNP has been the subject of a number of other reports. Piper Sandler cut Horizon Therapeutics Public from an overweight rating to a neutral rating […] ....
StockNews.com initiated coverage on shares of Horizon Therapeutics Public (NASDAQ:HZNP – Get Rating) in a research report sent to investors on Monday. The brokerage issued a buy rating on the biopharmaceutical company’s stock. A number of other equities research analysts have also commented on the stock. Stifel Nicolaus lowered shares of Horizon Therapeutics Public from […] ....
StockNews.com assumed coverage on shares of Horizon Therapeutics Public (NASDAQ:HZNP – Get Rating) in a research report report published on Monday morning. The firm issued a buy rating on the biopharmaceutical company’s stock. Several other brokerages have also issued reports on HZNP. Stifel Nicolaus lowered Horizon Therapeutics Public from a buy rating to a hold […] ....
Carnegie Capital Asset Management LLC bought a new position in shares of Horizon Therapeutics Public Limited (NASDAQ:HZNP – Get Rating) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 2,138 shares of the biopharmaceutical company’s stock, valued at approximately $243,000. […] ....